2019 American Transplant Congress
Technology Triggered Adherence Intervention – Preliminary Findings
1University of Cincinnati, Cincinnati, OH, 2UC Health, Cincinnati, OH
*Purpose: Medication non-adherence (M-NA) after renal transplant (RT) increases the risk of graft failure. We conducted a prospective, randomized, single center trial to evaluate 3…2019 American Transplant Congress
Efficacy and Safety of Alemtuzumab versus Basiliximab Induction in Lung Transplantation
Temple University Hospital, Philadelphia, PA
*Purpose: Minimal literature exists regarding alemtuzumab for induction in lung transplantation but is the preferred agent at Temple University Hospital (TUH). Basiliximab is reserved for…2018 American Transplant Congress
Patient Experience after Kidney Transplant: Factors That Lessen the Burden of Treatment after Kidney Transplant
1Mayo Clinic, Rochester; 2Mayo Clinic, Scottsdale; 3Mayo Clinic, Jacksonville.
Background: Patients face a daunting regimen of medications, health monitoring and medical appointments following kidney transplant. This workload of healthcare and its impact on patient…2018 American Transplant Congress
Belatacept and Tacrolimus Corticosteroid-Free Regimens Lead to Elevated Mycophenolic Acid Exposure at 1 and 3 Months after Kidney Transplantation
Mycophenolate mofetil (MMF) is generally administered as a fixed dose. Studies have shown a relationship between MPA exposure (MPAAUC) but no data evaluates this relationship…2018 American Transplant Congress
Efficacy and Safety of a Single-Dose Rituximab for Prevention of Focal Segmental Glomerulosclerosis Recurrence after Kidney Transplant
Background: For patients with end stage renal disease (ESRD) due to primary focal segmental glomerulosclerosis (FSGS), there is a significantly increased risk for disease recurrence…2018 American Transplant Congress
The Infusion with a Difference: Patient Experiences with Belatacept
Yale University, New Haven, CT.
Introduction: The results of the BENEFIT trial led to the FDA approval of the novel anti-rejection agent belatacept (bela) in 2011. In addition to its…2018 American Transplant Congress
Conversion from Twice Daily Immediate Release Tacrolimus to Once Daily Extended Release Tacrolimus (LCP-Tacro) in High Risk Kidney Transplant Recipients
Extended release once daily tacrolimus (LCP-Tacro) has demonstrated non inferiority to immediate release twice daily tacrolimus (IR-Tac) in kidney transplantation. These data are limited by…2018 American Transplant Congress
Side Effect Profile of Everolimus in Liver Transplant Patients
IntroductionUse of calcineurin inhibitors has been the mainstay of antirejection medications after liver transplant (LT). However, renal toxicity from these drugs remains troublesome. By comparison,…2018 American Transplant Congress
Safety and Tolerability of Therapy for Latent Tuberculosis Infection: A 16-Year Review
Transplant Infectious Diseases, UHN, Toronto, ON, Canada.
Introduction:Screening and therapy of latent tuberculosis infection (LTBI) is recommended in transplant candidates. However, data on therapy of LTBI with fluoroquinolones are limited. We aimed…2018 American Transplant Congress
Isavuconazole – The Real-World Use Experience
Cleveland Clinic Foundation, Cleveland, OH.
Isavuconazole (ISV) is a new triazole approved for treatment of mucormycosis and aspergillosis. Data on its effectiveness outside clinical trials and in patients receiving prior…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 18
- Next Page »